The Initiative for Multipurpose Prevention Technologies (IMPT) develops tools and resources to inform MPT product development and investment decisions and to educate other interested stakeholders. .
|
TRIO Study Brief: Long-Acting Injections for Women’s HIV Prevention in Sub-Saharan Africa: What End-Users Think | |
|
This brief features findings from the Tablets, Ring, Injections as Options (TRIO) study, with a focus on long-acting injections as a delivery form for HIV prevention for women and a potential delivery form for MPTs.
With injections as a new biomedical HIV prevention strategy on the horizon, the TRIO study's end-user findings from women and healthcare providers, as outlined in this brief, provide a timely contribution to late-stage product development. Further, they inform market introduction considerations for rollout of injectable delivery forms for women.
TRIO was a multiphase study conducted with young women in Kenya and South Africa between 2015 and 2017 to understand their perspectives on future MPTs. It was led by RTI International with support from the Bill & Melinda Gates Foundation.
|
|
|
TRIO General Research Brief: What End-Users Think About HIV Prevention Products and Multipurpose Prevention Technologies (MPT) | |
|
This factsheet features the main findings from the Tablets, Ring, Injections as Options study (TRIO), a multiphase study conducted with young women in Kenya and South Africa between 2015 and 2017 to understand their perspectives on future MPTs. TRIO identified anticipated enablers and barriers to adoption and use of future MPTs, explored preferred product characteristics, and solicited novel product design recommendations. The study was led by RTI International with support from the Bill & Melinda Gates Foundation.
|
|
|
TRIO MPT Research Brief: Listening to Young Women in Kenya and South Africa to Inform Multipurpose “2-in-1” Products for HIV and Pregnancy Prevention | |
|
This MPT-focused research brief, published by Tablets, Ring, Injections as Options (TRIO) - a multiphase study conducted with young women in Kenya and South Africa between 2015 and 2017 - showcases study findings on product preferences, choice and use among young women in Kenya and South Africa. It also notes health system benefits and resource challenges identified by healthcare providers. It makes the case for developing 2-in-1 products that offer choices for pregnancy and HIV prevention and meet women’s lifestyle needs as a way to increase product adoption and adherence.
|
|
|
Toward a Roadmap for Biomedical HIV Prevention Investment Standards: Strategic Insights from Key Industry Stakeholders | |
|
The United States Agency for International Development (USAID) is a major funder of biomedical HIV prevention product development. In response to USAID’s desire for standards to help guide decisions for prioritizing investments and integrating user perspectives at various stages of product development, the Initiative for MPTs (IMPT) provided technical assistance to USAID’s Office of HIV/AIDS (OHA) to develop a Biomedical HIV Prevention Product Investment Framework.
|
|
|
Market Access Framework for MPT Development | |
|
This framework is intended to serve as a resource to inform product development and investment decision-making that is focused specifically on market access components of MPT development and introduction—in other words, activities that are critical to ensuring that MPTs in development are not only efficacious in clinical trials, but also desired, acceptable, and accessible to women and adolescent girls once introduced and commercially available.
|
|
